Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Accounts Payables (2022 - 2025)

Historic Accounts Payables for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Addex Therapeutics' Accounts Payables rose 4361.0% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 4361.0%. This contributed to the annual value of $903435.7 for FY2024, which is 6597.02% down from last year.
  • According to the latest figures from Q3 2025, Addex Therapeutics' Accounts Payables is $1.5 million, which was up 4361.0% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Addex Therapeutics' Accounts Payables peaked at $4.2 million during Q2 2022, and registered a low of $907266.7 during Q4 2024.
  • Moreover, its 4-year median value for Accounts Payables was $2.7 million (2023), whereas its average is $2.4 million.
  • Over the last 5 years, Addex Therapeutics' Accounts Payables had its largest YoY gain of 4361.0% in 2025, and its largest YoY loss of 7222.5% in 2025.
  • Addex Therapeutics' Accounts Payables (Quarter) stood at $3.1 million in 2022, then decreased by 13.57% to $2.7 million in 2023, then plummeted by 66.25% to $907266.7 in 2024, then skyrocketed by 60.84% to $1.5 million in 2025.
  • Its Accounts Payables stands at $1.5 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.1 million for Q1 2025.